Difference between revisions of "Blastic plasmacytoid dendritic cell neoplasm"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf" to "https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1411") |
Warner-admin (talk | contribs) m (Text replacement - "==[https://www.nccn.org/ NCCN]==" to "==NCCN==") |
||
| Line 11: | Line 11: | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
=Guidelines= | =Guidelines= | ||
| − | == | + | ==NCCN== |
*''NCCN does not currently have guidelines at this granular level; please see [https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1411 NCCN Guidelines - Acute Myeloid Leukemia].'' | *''NCCN does not currently have guidelines at this granular level; please see [https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1411 NCCN Guidelines - Acute Myeloid Leukemia].'' | ||
*'''2023:''' Pollyea et al. [https://doi.org/10.6004/jnccn.2023.0025 Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology] [https://pubmed.ncbi.nlm.nih.gov/37156478/ PubMed] | *'''2023:''' Pollyea et al. [https://doi.org/10.6004/jnccn.2023.0025 Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology] [https://pubmed.ncbi.nlm.nih.gov/37156478/ PubMed] | ||
Revision as of 11:29, 13 May 2024
| Section editor | |
|---|---|
 |
Ashwin Kishtagari, MD Vanderbilt University Nashville, TN, USA |
1 regimens on this page
1 variants on this page
|
Guidelines
NCCN
- NCCN does not currently have guidelines at this granular level; please see NCCN Guidelines - Acute Myeloid Leukemia.
- 2023: Pollyea et al. Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology PubMed
All lines of therapy
Tagraxofusp monotherapy
Regimen
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Frankel et al. 2014 (STU 012013-061) | 2013-NR | Phase 1/2, fewer than 20 pts |
| Pemmaraju et al. 2019 (STML-401-0114) | 2014-2017 | Phase 1/2 (RT) |
Targeted therapy
- Tagraxofusp (Elzonris) 12 mcg/kg IV over 15 minutes once per day on days 1 to 5
21-day cycles
References
- STU 012013-061: Frankel AE, Woo JH, Ahn C, Pemmaraju N, Medeiros BC, Carraway HE, Frankfurt O, Forman SJ, Yang XA, Konopleva M, Garnache-Ottou F, Angelot-Delettre F, Brooks C, Szarek M, Rowinsky E. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014 Jul 17;124(3):385-92. Epub 2014 May 23. link to original article link to PMC article PubMed NCT00397579
- STML-401-0114: Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, Rizzieri DA, Wang ES, Duvic M, Sloan JM, Spence S, Shemesh S, Brooks CL, Balser J, Bergstein I, Lancet JE, Kantarjian HM, Konopleva M. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019 Apr 25;380(17):1628-1637. link to original article contains dosing details in manuscript PubMed NCT02113982
- Update: Pemmaraju N, Sweet KL, Stein AS, Wang ES, Rizzieri DA, Vasu S, Rosenblat TL, Brooks CL, Habboubi N, Mughal TI, Kantarjian H, Konopleva M, Lane AA. Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm. J Clin Oncol. 2022 Sep 10;40(26):3032-3036. Epub 2022 Jul 12. link to original article link to PMC article PubMed